不良事件与严重不良事件的重叠:一项III期癌症临床试验案例研究
该研究基于ICON8卵巢癌临床试验,探讨不良事件(AE)与严重不良事件(SAE)两个数据集报告的系统性重叠情况及其对安全性分析的影响。结果显示仅61%的SAE元素可匹配至已报告的AE,补充未匹配事件后,各治疗组发生≥3级安全事件的患者比例均有升高,提示仅用AE数据集分析可能遗漏重要安全性信息。
要点
- 仅61%的SAE元素可匹配到已报告的AE,近40%未匹配。
- 补充未匹配SAE后,对照组≥3级事件患者比例从42%升至47%。
- 仅用AE数据集或未明确纳入SAE的分析可能遗漏重要安全性信息。
核心结论
- SAE与已报告AE的匹配一致性低,近40%纳入映射的SAE未匹配到已报告AE。
- 仅使用AE数据集或未明确考虑SAE数据的安全性分析很可能遗漏重要安全性信息。
- 报告标准应明确说明分析所使用的数据集。
研究设计与样本
- 基于III期卵巢癌临床试验ICON8的安全性数据开展案例研究。
- 对SAE数据进行文本检索,按预设标准(事件术语匹配、发病与评估日期相差30天内、评估日期在发病与缓解之间、同一化疗周期确认)映射至AE数据。
- 构建包含所有独特安全事件的合并数据集并重新进行安全性分析。
主要发现
- 61%的SAE元素匹配到已报告的AE。
- 补充额外安全事件后,对照组至少发生1次≥3级安全事件的患者比例从42%升至47%,两个研究组分别从61%升至65%、从52%升至59%。
- 研究组相比对照组的≥3级事件比例差异分别改变了18%(95%CI 12至24%)和12%(95%CI 6至18%)。
关键数值与推荐
- SAE映射至AE的预设标准包括:事件术语匹配、发病日期与评估日期相差在30天内、评估日期位于发病与缓解日期之间、确认事件发生于同一化疗周期。
临床怎么用
- 安全性分析应同时考虑AE和SAE数据集,或明确说明仅使用AE数据集可能遗漏SAE信息。
- 报告安全性结果时应明确说明分析所使用的数据集。
局限性
- 原文未报告
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Safety data is required to be collected in all clinical trials and can be separated into two types of data, adverse events and serious adverse events. Often, these types of safety data are collected as two discrete data sets, where adverse events that also meet the criteria for seriousness should be reported in both datasets. Safety analyses are often conducted using only the adverse event dataset, which should feature all safety events reported. We investigated whether the reporting of safety in both datasets was systematically followed and explored the impact of this on safety analyses in ICON8, an ovarian cancer clinical trial. METHODS: Text searches of serious adverse event data identified events that could potentially match the data reported in the adverse event dataset (looking at pre-specified AE terms only). These serious adverse events were then mapped to adverse event data according to predefined criteria: (a) event term matches, (b) date of onset and date of assessment within 30 days of each other, (c) date of assessment lies between date of onset and date of resolution and (d) events confirmed to occur in the same chemotherapy cycle. A combined dataset of all unique safety events (whether originally reported in the adverse event or serious adverse event dataset) was created and safety analyses re-performed. RESULTS: 51,019 adverse events were reported in ICON8, of which 42,410 were included in the mapping exercise. One thousand five hundred six serious adverse event elements were reported, of which 668 were included in the mapping exercise. Sixty-one percent of serious adverse event elements was matched to an already-reported adverse event. Supplementing these additional safety events and re-performing safety analyses increased the proportion of patients with at least one grade 3 or worse safety events in all arms from 42 to 47% in the control arm and 61 to 65% and 52 to 59% in the research arms. The difference in proportions of grade 3 or worse event in the research arms compared to the control arm changed by 18% (95% confidence interval [CI] 12 to 24%) and 12% (95% CI 6 to 18%), respectively. CONCLUSIONS: There was low agreement in mapping serious adverse events to already reported adverse events, with nearly 40% of serious adverse events included in the mapping exercise not mapped to an already reported adverse event. Any analyses of safety data that use only adverse event datasets or do not clearly account for serious adverse event data will likely be missing important safety information. Reporting standards should make clear which datasets were used for analyses.
引用
- James EC, Dunn D, Cook AD, et al. Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial. Trials. 2020. PMID: 32943106. doi:10.1186/s13063-020-04718-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。